-
Rona Therapeutics’ RN0191 Showcases Positive Phase I Results at AHA Scientific Sessions
•
Shanghai-based nucleic acid drug developer Rona Therapeutics has announced the presentation of positive Phase I results for its investigational drug, RN0191, at the American Heart Association’s (AHA) Annual Scientific Sessions in Chicago, IL. The study’s findings highlight the potential of RN0191 in managing lipid levels and offer promising news for…
-
Youjia Biomedical and Yiling Pharmaceutical Collaborate on RNAi Metabolic Disease Treatments
•
China-based Youjia (Hangzhou) Biomedical Technology Co., Ltd, a leading nucleic acid technology developer, has entered into a strategic cooperation agreement with Yiling Pharmaceutical Co., Ltd (SHE: 002603), marking a significant step into the metabolic diseases field utilizing RNAi technologies. This partnership aims to leverage Youjia’s expertise in nucleic acid drug…
-
Mirxes Holding Company Updates IPO Prospectus with 2024 Financials
•
Mirxes Holding Company Ltd, a Singapore-based RNA technology company specializing in blood-based miRNA test kit products, has submitted an updated initial public offering (IPO) prospectus to the Hong Kong Stock Exchange. The document reveals the company’s financial performance as of June 2024. During the first half of the year, Mirxes…
-
Youcare Pharmaceutical Group Gets NMPA Approval for YKYY015 Phase I Study
•
China-based Youcare Pharmaceutical Group (SHA: 688658) has announced that it has received approval from the National Medical Products Administration (NMPA) to initiate a Phase I clinical study for its investigational drug YKYY015, targeting primary hypercholesterolemia or mixed hyperlipidemia characterized by elevated LDL-C levels. YKYY015, an siRNA drug, is distinctive for…
-
AstraZeneca’s Wainzua Earns CHMP Nod for hATTR-PN Treatment in the EU
•
UK pharmaceutical juggernaut AstraZeneca (AZ, NASDAQ: AZN) has announced that Wainzua (eplontersen), an RNA-targeted therapy co-developed with US-based Ionis Pharmaceuticals (NASDAQ: IONS), has received a positive recommendation for approval from the Committee for Medicinal Products for Human Use (CHMP) within the European Union (EU). The treatment is intended for adults…
-
Eli Lilly Partners with Haya Therapeutics to Tap the Dark Genome for Obesity Treatments
•
Eli Lilly & Co. (NYSE: LLY), a leading figure in the pharmaceutical industry, has embarked on a drug discovery partnership with Switzerland’s Haya Therapeutics, a move that underscores its commitment to advancing its anti-obesity portfolio. The collaboration will tap into Haya’s cutting-edge expertise in the dark genome, the largely non-protein-coding…
-
Novartis and Versant Ventures Launch Borealis Biosciences with a Focus on RNA Medicines for Kidney Diseases
•
Novartis (NYSE: NVS), a Swiss pharmaceutical heavyweight, has joined forces with the US venture capital fund Versant Ventures to launch Borealis Biosciences, a cutting-edge biotech firm dedicated to pioneering next-generation RNA medicines for kidney diseases. Borealis emerges from incubation with a substantial USD 150 million in Series A financing, bolstered…
-
Innovent Biologics and Sanegene Bio Commence Phase I Clinical Trial for Hypertension siRNA Drug
•
Innovent Biologics Inc. (HKG: 1801), a leading biopharmaceutical company based in China, in collaboration with Sanegene Bio USA Inc., has announced the dosing of the first patient in a Phase I First-in-Human (FIH) clinical trial for their siRNA drug candidate, IBI3016. This investigational therapy targets angiotensinogen (AGT) and is being…
-
Rona Therapeutics Secures USD 35 Million in Series A+ Round to Advance Nucleic Acid Therapies
•
Rona Therapeutics, a Shanghai-based nucleic acid drug developer, has secured USD 35 million in a Series A+ financing round led by LongRiver Investments. The funding round also saw participation from Zhaode Investment, Zhongqi Capital, BioTrack Capital, and Lilly Asia Ventures. The company plans to utilize the proceeds to accelerate its…
-
AusperBio Secures $37 Million in Series A Funding to Advance Hepatitis B Therapy AHB-137
•
AusperBio, a sino-American biotechnology company specializing in liver therapy development, has reportedly secured USD 37 million in a Series A financing round. The round was spearheaded by the InnoPinnacle Fund, with additional investments from a consortium that includes Yuanbio Venture Capital, Hankang Capital, Qiming Venture Partners, and Genesis Capital. The…
-
Suzhou Sanegene Bio Receives NMPA Approval for Clinical Trial of Antihypertensive siRNA Drug
•
Suzhou Sanegene Bio Inc., a leading RNAi specialist with research and development centers in both the US and China, has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its investigational drug SGB-3908. This antihypertensive siRNA drug has been co-developed with Innovent Biologics,…
-
Sirnaomics’ STP122G Achieves Phase I Milestone with Positive Interim Data for Anticoagulation Treatment
•
Sirnaomics Ltd (HKG: 2257) has announced the completion of the Phase I second sequence for its drug candidate STP122G, which is being developed as an anticoagulation treatment, along with the release of interim data. The Factor XI program, to which STP122G belongs, has broad therapeutic potential as an anticoagulant across…
-
Sirnaomics Receives FDA Feedback on STP705 Development Plan for isSCC Treatment
•
Sirnaomics Ltd (HKG: 2257), a leading biopharmaceutical company focused on the discovery and development of RNAi therapeutics, has announced receiving a written response from the U.S. Food and Drug Administration (FDA) regarding the required Class C meeting for STP705, a treatment for in situ squamous cell carcinoma (isSCC). The Class…
-
Arnatar Therapeutics Secures $50 Million in Series A Funding to Expand into China
•
US-based biotechnology company Arnatar Therapeutics has successfully closed a $50 million Series A financing round, marking a significant step in the firm’s expansion plans into the Chinese market. The funding round, co-led by 3E Bioventures and Eight Roads, attracted substantial Chinese investment, highlighting the growing interest in innovative biotech solutions…
-
Shanghai Medicilon Forms Strategic Partnerships with Binhui Biopharmaceutical and Innoforce Pharmaceuticals
•
Shanghai Medicilon Biomedical Co., Ltd (SHA: 688202), a prominent Chinese biotech firm, has entered into separate partnerships with domestic companies Binhui Biopharmaceutical and Innoforce Pharmaceuticals Co., Ltd. In collaboration with Binhui, Medicilon aims to explore innovative areas including oncolytic viruses, nucleic acid drugs, and protein therapeutics. Meanwhile, the partnership with…
-
HitGen Secures CDE Approval for Lipisense IND Filing, Advancing Development for Dyslipidemia Treatment
•
HitGen Inc., (SHA: 688222) a China-based pharmaceutical company, has announced that the Investigational New Drug (IND) filing for its Lipisense (A24110He for injection) has received approval from China’s Center for Drug Evaluation (CDE). Lipisense, an innovative antisense oligonucleotide (ASO) drug originally developed by Swiss firm Lipigon Pharmaceuticals AB, is designed…
-
AstraZeneca Launches Phase I Trial for siRNA Therapy in Collaboration with Silence Therapeutics
•
AstraZeneca (AZ; NASDAQ: AZN) has commenced a Phase I trial for a short interfering RNA (siRNA) therapy targeting an undisclosed disease, marking the first clinical candidate to emerge from its 2020 collaboration with UK-based Silence Therapeutics (NASDAQ: SLN). This partnership aims to develop up to ten siRNA therapeutics across cardiovascular,…
-
Visirna Therapeutics Completes Enrollment in Phase III Study for FCS Drug VSA001
•
Visirna Therapeutics, a Shanghai-based biopharmaceutical company, has announced the completion of patient enrollment in a Phase III clinical study for its investigational drug VSA001, which is being studied for the treatment of familial chylomicronemia syndrome (FCS) in China. A total of 36 FCS patients have been enrolled and will be…
-
Novartis Strikes Deal with Argo Biopharma for Global Rights to siRNA Drug Candidates
•
Argo Biopharma, a Shanghai-based developer of small interfering RNA (siRNA) drugs, has secured a licensing agreement with Novartis (NYSE: NVS), the Swiss pharmaceutical giant. The deal grants Novartis global rights to a Phase I drug candidate and ex-Greater China rights to another program currently in Phase I/IIa. In return, Argo…
-
Boehringer Ingelheim Partners with Suzhou Ribo Life Science to Develop siRNA Therapies for NASH/MASH
•
Boehringer Ingelheim (BI), a Germany-headquartered pharmaceutical company, has entered into a collaboration agreement with Suzhou Ribo Life Science Co., Ltd, a Chinese biotechnology firm, to co-develop small interfering RNA (siRNA) drugs for the treatment of non-alcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH). This strategic partnership aims to leverage Ribo’s proprietary RIBO-GalSTAR…
-
Innovent Biologics Partners with Sanegene Bio USA to Develop Hypertension Drug
•
China-based Innovent Biologics (HKG: 1801) has entered into a partnership with Sanegene Bio USA Inc. to co-develop the small interfering RNA (siRNA) candidate drug SGB-3908 for the treatment of hypertension. Innovent Biologics has secured the exclusive option to license global development, manufacturing, and commercialization rights for the drug. Upon the…
-
Suzhou Ribo Life Science Strikes Deal with Qilu Pharmaceutical for PCSK9 siRNA Drug
•
Suzhou Ribo Life Science Co., Ltd, a specialist in small interfering RNA (siRNA) drugs based in China, has entered into a licensing agreement with Qilu Pharmaceutical, granting the company clinical development, manufacturing, and commercialization rights to its PCSK9 siRNA drug RBD7022 in Greater China, which includes mainland China, Hong Kong,…
-
SanegeneBio Secures Over USD 80 Million in Series A+ Funding to Advance RNAi Therapeutics
•
SanegeneBio, a Suzhou-based developer of RNA interference (RNAi) therapeutics, has successfully raised over USD 80 million in a Series A+ financing round co-led by Tencent Investment and YuanBio Venture Capital. The funding round also saw participation from Northern Light Venture Capital, C&D Emerging Industry Equity Investment, Yuanhe Holding, Shanghai Healthcare…
-
BMS and Avidity Biosciences Join Forces on $2.2 Billion Cardiology Antibody Oligonucleotide Conjugate Deal
•
Bristol Myers Squibb (BMS, NYSE: BMY) has announced a strategic partnership with Avidity Biosciences (NASDAQ: RNA) focused on the discovery, development, and commercialization of cardiology-oriented antibody oligonucleotide conjugates (AOCs). This innovative class of RNA therapeutics merges the specificity of monoclonal antibodies with the precision of oligonucleotide therapies, building on insights…
-
SanegeneBio Partners with Huadong Medicine to Develop RNAi Therapeutics for Metabolic Diseases
•
Suzhou-based RNA interference (RNAi) therapeutics developer SanegeneBio has entered into a partnership with compatriot firm Huadong Medicine Co., Ltd (SHE: 000963). The collaboration will utilize SanegeneBio’s Ligand and Enhancer Assisted Delivery (LEAD) technology platform to develop small interfering RNA (siRNA) drugs targeting chronic metabolic diseases, with the potential to expand…
-
XtalPi Inc. and CK Life Sciences Expand Partnership to Develop AI-Powered Cancer Diagnostics
•
Sino-US artificial intelligence (AI) firm XtalPi Inc. has announced a strategic partnership agreement with China-based CK Life Sciences (HKG: 0775). The collaboration aims to leverage AI and clinical diagnosis data, including biomarker information from cancer patients and healthy populations, to develop molecular diagnostic models that predict cancer prognosis risk based…
-
Sirnaomics’ STP705 Demonstrates Positive Results in Phase I Focal Fat Reduction Study
•
Sirnaomics Ltd (HKG: 2257) has announced positive safety and efficacy results from a Phase I clinical study for its investigational product, STP705, which is focused on focal fat reduction (FFR). The study provides valuable insights into the potential of STP705 as a non-invasive treatment for reducing fat accumulation in specific…
-
Hotgen Biotech Partners with Genoval Therapeutics for RNAi Drug Development
•
China’s Hotgen Biotech Co., Ltd (SHA: 688068) has announced a strategic partnership between its anti-aging focused controlling subsidiary and Genoval Therapeutics Co., Ltd, a Shanghai-based developer of RNAi therapeutics. The collaboration aims to advance the development of multiple pioneering small nucleic acid drugs targeting the liver and extrahepatic tissues, addressing…
-
CNIPA Upholds Alnylam’s PCSK9-Targeted siRNA Patent Against Junshi Biosciences Challenge
•
The China National Intellectual Property Administration (CNIPA) has rejected another challenge from Junshi Biosciences (SHA: 688180) against an Alnylam Pharmaceutical (NASDAQ: ALNY) patent (ZL201810143112.0) related to the development of PCSK9-targeted small-interfering RNA (siRNA) therapies. This decision ensures the patent’s validity remains intact until December 5, 2033. Details of the Patent…
-
Novartis Launches Leqvio in China at RMB 9,988 per Shot
•
Swiss pharmaceutical giant Novartis (NYSE: NVS) has officially launched its cholesterol-lowering drug, Leqvio (inclisiran), in China, priced at RMB 9,988 (approximately USD 1,367) per injection. Each pre-filled syringe contains 1.5ml with an effective content of 284mg. The drug is recommended for subcutaneous administration, with a second dose administered three months…
-
Sirius Therapeutics Secures USD 60 Million in Series B Financing for siRNA Therapy Development
•
Sirius Therapeutics, a Shanghai-based developer of siRNA therapies, has successfully raised USD 60 million in a Series B financing round. This funding is specifically allocated for the clinical development of its siRNA therapy product pipelines and the advancement of next-generation nucleic acid molecular delivery technologies. The financing round was led…
